Zelluna Asa · OSL:ZLNA
Zelluna Asa — Ultimovacs — Q1 2020 Earnings Presentation
13 slides from Zelluna Asa's earnings presentation, May 14, 2020
Slide 1: Activating the immune system to fight cancer – First quarter 2020 presentation
Activating the immune system to fight cancer First quarter 2020 presentation 14 May 2020 Øyvind Kongstun Arnesen, CEO Jens Bjørheim, CMO Hans Vassgård Eid, CFO | Carlos de Sousa, CEO from 1 June 2020
Slide 2: Important notice and Disclaimer
Important notice and Disclaimer This presentation may contain certain forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Ultimovacs’ business, financia
Slide 3: Highlights Q1 2020
Highlights Q1 2020 Expected initiation of patient inclusion in the INITIUM and NIPU trials in March 2020 was halted due to the covid-19 situation However, the first hospitals in both the INITIUM and the NIPU trial are now open for patient inclusion The corona pandemic has increased the risk for a pr
Slide 4: Ultimovacs – Development Plan
Ultimovacs – Development Plan 2018 2019 2020 2021 2022 2023 Phase I trial (first line metastatic malignant melanoma with combination UV1/pembrolizumab) Ultimovacs sponsored UV1 INITIUM: Phase II proof of concept trial (first line metastatic malignant melanoma with triple combination ipilimumab/nivol
Slide 5: Highlights – Q1 2020: Clinical trial update
Highlights – Q1 2020: Clinical trial update Ongoing US based phase I trial study in malignant melanoma UV1 is given in combination with the PD-1 checkpoint inhibitor pembrolizumab All 20 of the initially planned patients have been successfully included (cohort 1 – safety pembrolizumab/UV1) In Septem
Slide 6: Highlights – Q1 2020: Clinical trial update (cont.)
Highlights – Q1 2020: Clinical trial update (cont.) The INITIUM trial (randomized phase II trial in malignant melanoma) UV1 will be given in combination with the CTLA-4 checkpoint inhibitor ipilimumab and the PD-1 checkpoint inhibitor nivolumab 154 patients, first patient was expected Q1 2020, but s
Slide 7: Highlights – Q1 2020: Clinical trial update (cont.)
Highlights – Q1 2020: Clinical trial update (cont.) The NIPU trial (randomized phase II trial in malignant pleural mesothelioma) UV1 will be given in combination with the CTLA-4 checkpoint inhibitor ipilimumab and the PD-1 checkpoint inhibitor nivolumab 118 patients, first patient expected Q1 2020,
Slide 8: Key financials
Key financials Key financials per Q1-2020 - Ultimovacs Group Comments: NOK (000) Q1-19 Q1-20 FY19 Payroll expenses Total revenues 0 0 0 Higher cost in Q1-20 than Q1-19 primarily due Payroll and payroll related expenses 7 538 10 015 20 160 to 3 more FTEs External R&D and IPR expenses (incl. grants) 4
Slide 9: Key financials – operating cash flow
Key financials – operating cash flow NOK (000) Comments: Relatively stable operating cash flow per quarter historically, however a significant increase in Q1-20 due to higher R&D activities Operating cash outflows expected to increase significantly during FY20 with the commencement of planned projec
Slide 10: Key financials – quarterly overview
Key financials – quarterly overview Key financials per Q1-2020 - Ultimovacs Group NOK (000) Q1-18 Q2-18 Q3-18 Q4-18 Q1-19 Q2-19 Q3-19 Q4-19 Q1-20 FY19 Total revenues 0 0 0 0 0 0 0 0 0 0 Payroll and payroll related expenses 6 355 4 128 9 454 7 141 7 538 -4 717 8 653 8 686 10 015 20 160 External R&D a
Slide 11: Carlos de Sousa – new CEO from 1 June 2020
Carlos de Sousa – new CEO from 1 June 2020 Personal introduction | 11
Slide 12: For questions
For questions Øyvind Kongstun Arnesen, CEO E-mail: oeyvind.arnesen@ultimovacs.com Phone: +47 469 33810 Hans Vassgård Eid, CFO E-mail: hans.eid@ultimovacs.com Phone: +47 482 48632 | 12
Slide 13: Q&A
Q&A |